focus -WSS

focus

author：explore 2025-10-04 04:01:58 - browse：92

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The cancer stories no one wants to hear

WSS

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Alnylam reports growth in sales of rare disease treatments

Greece's new parliament sworn in following conservative party's election victory

2 officers injured in shooting in Orlando, police say

Group behind ProMed defends move to subscription

focus

focus

focus

Medical records are filled with copy

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Medical records are filled with copy

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Activists slam private health insurers over coverage restrictions

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

H.R. 3 is the wrong path to lower drug costs

Apple is now the first public company to be valued at $3 trillion

Pharma showers House GOP doctor with campaign cash

focus

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

The a glaring gap in research on serious mental illness and primary care

hotspot

leisure time

hotspot

entertainment